INTRODUCTION
Patients with BLBC show reduced survival compared to those with more common luminal tumors, and this disease frequently occurs in young patients, as well as in women with African ancestry. Basal-like tumors express markers of myoepithelium, but show a gene expression signature related to that of luminal progenitor cells (Cheang et al., 2008; Lim et al., 2009 ; Perou
Significance
Here we report that LFNG, which suppresses Jagged/Notch signaling in vivo, is consistently expressed at a low level in basal-like tumors and deletion of this gene in the mouse mammary gland enhances accumulation of activated Notch intracellular domain polypeptides, increases proliferation, and induces basal-like mammary tumors in cooperation with amplification of the Met/Caveolin gene locus. These mutations interact to promote a specific BLBC signaling network with increased Notch pathway activation, as well as elevated Met and Igf-1R signaling. Patients with MET/CAV-overexpressing BLBC may therefore benefit from combination therapy targeting Notch, MET, and IGF1R.
and Børresen-Dale, 2011; Prat et al., 2010) . Indeed, luminal progenitors may be the cell-of-origin for most BLBC (Molyneux et al., 2010) . In the mouse system, activated Notch1 can induce commitment of mammary stem cells (MaSC) into luminal progenitors, and promote proliferation of luminal progenitor cells in vitro and in vivo (Bouras et al., 2008) . Similarly in humans, increased NOTCH3 expression and function can promote luminal progenitor cell fate specification, at least in vitro (Raouf et al., 2008) .
On the basis of studies with the Mouse Mammary Tumor Virus (MMTV), which can induce mammary tumor formation through insertional activation of Notch genes, a role for Notch signaling in human breast cancer was anticipated (Callahan and Smith, 2000) . Most human breast tumors express Notch ligands and receptors (Parr et al., 2004; Pece et al., 2004; Reedijk et al., 2005; Stylianou et al., 2006) . High-level expression of the JAGGED1 ligand, as well as NOTCH1 and/or NOTCH3, is associated with poor overall survival (Reedijk et al., 2005) . Recent studies reveal that signaling through multiple Notch receptors activates proliferation and/or survival of breast cancer cells (Harrison et al., 2010; Haughian et al., 2012; Osipo et al., 2008; Sansone et al., 2007; Yamaguchi et al., 2008) . Interestingly, JAGGED-dependent Notch pathway activation has been associated with triple negative (ERa À , PR À, and HER2 À ) tumors, and specifically with basal-like tumors and cell lines Dong et al., 2010; Haughian et al., 2012; Lee et al., 2008a Lee et al., , 2008b Leong et al., 2007; Reedijk et al., 2008; Sansone et al., 2007) . Met, a cell surface tyrosine kinase receptor involved in epithelial-mesenchymal transition, is frequently expressed at high levels in BLBC (Elsheikh et al., 2008; Gastaldi et al., 2010; Lu et al., 2008; Ponzo and Park, 2010; Ravid et al., 2005; Salani et al., 2008; Savage et al., 2007) , and many basal-like tumors show elevated Met signaling (Hochgrä fe et al., 2010) . In addition, Caveolin1 and 2, which facilitate Igf-1R signaling, are also overexpressed (Elsheikh et al., 2008; Gastaldi et al., 2010; Lu et al., 2008; Ponzo and Park, 2010; Ravid et al., 2005; Salani et al., 2008; Savage et al., 2007) . Interestingly, the genes coding for MET, CAV1, and CAV2 are located in the same region of Chromosome 7q31 and this locus is overexpressed in many BLBC (Elsheikh et al., 2008; Gastaldi et al., 2010; Ponzo and Park, 2010; Savage et al., 2007) .
Fringe proteins are N-acetylglucosamine transferases that modify Notch receptors to control ligand-mediated activation (Haines and Irvine, 2003) . These proteins enhance Notch activation by Delta-family ligands, while inhibiting Notch activation by Serrate/Jagged ligands (Haines and Irvine, 2003) . Lfng, one of three Fringe genes in mammals, controls Notch signaling in many developing tissues (Cohen et al., 1997; Johnston et al., 1997) . Interestingly, LFNG is expressed at high levels in MaSC and/or bipotent progenitor cells of the human breast (Raouf et al., 2008) . However, its role in the regulation of Notch signaling of the developing or adult mammary gland remains unknown, as is its potential for restricting Notch-dependent oncogenic signaling in this context. In this study, we used conditional mutant mice to define the function of Lfng in mammary epithelium. In addition, we tested for its expression and potential role in human breast cancer.
RESULTS

A Lfng Expression Boundary in Mammary Development
To define where and when Notch is activated in the developing mammary gland, we used LacZ knock-in mice for various Notch pathway genes. Typically, boundaries between Fringe-expressing cells and nonexpressing cells are sites of consequential Notch signaling (Irvine, 1999) . Therefore, we examined Lfng expression by performing X-gal staining on mammary glands from six-week-old Lfng LacZ/+ virgin females (Zhang and Gridley, 1998) . Interestingly, Lfng expression was restricted to basal cells, in particular to cap cells of terminal end buds (TEBs) (Figure 1A) , which have MaSC activity (Bai and Rohrschneider, 2010) . This result is consistent with studies on cells purified from the human mammary gland, which show that LFNG expression is > 20-fold enriched in stem and/or bipotent progenitor cells as compared with luminal restricted progenitors (Raouf et al., 2008 Figure 1A ). In mature adults, after TEB regression, Lfng lacZ expression was barely detected, while Dll1 lacZ expression remained strong in myoepithelial cells. Interestingly, Jagged1 expression switched from stroma to myoepithelium in the mature gland ( Figure 1A ). JAGGED1 expression is also high in basal cells of the mature human gland (Reedijk et al., 2005) . Next, we used antibodies to stain for Notch1 and Notch4, which were expressed at low levels in luminal and basal cells, respectively (Figure S1A available online). Using b-Geo/+ knock-in mice (Xu et al., 2010) , Notch3 expression was found to be high in body cells of the TEB, as well as in luminal epithelial cells of mature ducts, whereas Notch2 expression was strong in stroma and weak in epithelium (Figure S1B) . These data are consistent with recent Notch ligand and receptor expression analysis by rtPCR and immunohistochemistry (Bouras et al., 2008; Raafat et al., 2011; Raouf et al., 2008) .
Lfng Controls Notch Activation and Suppresses Mammary Epithelial Proliferation
Fringe controls Notch activation at compartment boundaries in the developing fruit fly (Irvine, 1999) . Our expression analysis in the mammary gland reveals a similar boundary at the TEB-ductal junction, where Lfng may differentially regulate Notch activation induced by Dll1 and/or Jagged1. To define Lfng function in this context, we analyzed mammary development in Lfng mutant mice. Whole-mount analysis showed evidence of epithelial hyperplasia in virgin mammary glands from Lfng mutants (Figure 1B) . Sections from mutant and control glands were stained with antibodies against luminal and basally restricted cytokeratins, keratin 8 (K8) and 14 (K14), respectively. Most mutant glands showed decreased K8 expression in body cells of the TEB. Also, multiple layers of K14 + basal cells were observed in some locations. Cells did not co-express K8 and K14 in wild-type or mutant glands during puberty ( Figure 1C ). We next tested for altered cell proliferation by staining for Ki67. Indeed, Lfng mutant glands showed increased cell proliferation in mature ducts ( Figure 1D) . TEBs and ducts are shown in upper and lower panels, respectively. (D) Ductal elongation at 6 weeks old, measured as the distance between the lymph node and the ductal front line normalized to the distance between the lymph node and the end of the fat pad, are presented as mean values ± standard error. *p < 0.05. Note, the Lfng null allele was generated through expression of Cre in the
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Fringe proteins control Notch signaling by enhancing Deltawhile inhibiting Serrate/Jagged-mediated activation (Haines and Irvine, 2003 ). Based on high-level Lfng expression in cap cells of the TEB, and the known cell autonomous function of Fringe proteins (Panin et al., 1997) , Lfng likely facilitates Dllmediated Notch signaling or blocks Jagged1-mediated Notch activation in MaSC and/or bipotential progenitors of the cap layer. The Transgenic Notch Reporter (TNR) mouse has an artificial Notch-responsive promoter with multiple RBPJk-binding sites regulating expression of eGFP (Duncan et al., 2005) . This mouse has been used successfully to study Notch/p63 interaction in the developing mammary gland (Yalcin-Ozuysal et al., 2010) . Therefore, to test for alterations in Notch signaling associated with Lfng deletion, we crossed TNR reporter mice with Lfng mutants. To follow Notch signaling at multiple levels within the developmental hierarchy, lineage-depleted mammary epithelial cells were stained for surface markers CD24, CD49f, CD61, and Sca1. Remarkably, Lfng null glands showed a more than 2-fold (2.37 ± 0.07, p < 0.05) enrichment of CD24 + CD49f hi cells, a population known to contain mammary stem/early progenitor cells ( Figure 1E ). We gated on this population and found that most cells were CD61 + Sca1
À , characteristic of MaSC (Visvader, 2009) (Figure 1E ). In some cases this was associated with decreased numbers of CD24 hi C49f + CD61 + luminal progenitor cells ( Figure 1E Figure S1C ). Specifically, in mutant mice, fewer cells with active Notch signaling were observed in MaSC/early progenitor-containing (CD24 +   CD49f hi ) and luminal progenitor-containing (CD24 hi CD49f + ) compartments ( Figure S1D ) Stingl et al., 2006) . Thus, deletion of Lfng leads to decreased Notch signaling in MaSC and progenitors in puberty (likely as a result of reduced Dll1-mediated Notch activation at this stage), and is associated with expansion of the immature cell compartment. These data are consistent with those of Bouras et al., who showed that shRNA-mediated knockdown of RBPJk, and thus disruption of canonical Notch signaling, caused expansion of the CD24 + CD29 hi compartment (note: this is the same as the CD24 + CD49f hi compartment), and promotion of MaSC self-renewal (Bouras et al., 2008) .
Lfng Is a Suppressor of Basal-like Tumor Formation in the Mouse Mammary Gland Next, we tested for Lfng function by generating a Cre-conditional Lfng mutant mouse (Xu et al., 2010) . This mouse was crossed to MMTV-Cre line A, which shows robust expression in mammary epithelium (Wagner et al., 1997) . Many Lfng flox/flox ; MMTV-Cre mutant mice developed mammary tumors starting at 10 months of age ( Figure 2A ). Histological analysis revealed three types of Lfng mutant tumors: approximately 60% showed glandular differentiation (type I); one-third mainly consisted of mesenchymal/spindle-shaped cells (type II); and about 5% had areas containing multinucleated giant cells (type III) ( Figure 2B ). All three histological types were triple-negative (ERa-, PR-, Her2/ Neu-negative) ( Figure 2C and data not shown), and highly proliferative ( Figure 2D ). Interestingly, tumors of all three types had cells co-expressing luminal (K8) and basal markers (K14). Notably, type I tumors contained a higher percentage (75.3% versus 16.8% in type II) of cells expressing one or both lineage-specific keratin ( Figure 2E ).
Next, we used transcriptional profiling to define molecular subtype for 11 Lfng mutant tumors (Herschkowitz et al., 2007) . Interestingly, in unsupervised cluster analysis, these tumors grouped with basal-like and claudin-low models but were otherwise quite unique. Specifically, six type I tumors clustered together with Brca1/p53 tumors, DMBA-induced tumors and Wap-SV40T
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-induced tumors, all of which are related to BLBC, whereas five spindle/EMT or type II Lfng mutant mammary tumors clustered nearby, together with DMBA-induced spindle tumors as well as with Brca1/p53 tumors, which have previously been identified as claudin-low (Herschkowitz et al., 2007) (Figures 3A and 3B ). The claudin-low signature is related to that observed in MaSCs (Hennessy et al., 2009 ). Interestingly, many mouse mammary tumors that were induced by activated Met cluster with similar basal-like mouse models (Ponzo et al., 2009) . We also performed enrichment map analysis to identify differentially expressed gene sets in Lfng flox/flox ; MMTV-Cre mammary tumors as compared to those expressed in other mouse breast cancer models. Interestingly, gene sets implicated in leukocyte activation and proliferation, inflammation, cytokine and chemokine signaling, as well as extracellular matrix remodeling were overrepresented in Lfng mutant tumors ( Figure 3C and Table S1 ).
We next analyzed tumors by flow cytometry. Lfng mutant tumors were composed of cells with marker profiles that were distinct from profiles seen in the normal mammary gland. ; TNR littermates at 6 weeks old. Shown are CD24/CD49f plots and Sca-1/CD61 plots on populations I, II, III gated as in CD24/CD49f plots. Scale bars correspond to 1 mm in left panels of (A), 5 mm in (B), and 50 mm in all others. See also Figure S1 . S2A) (Visvader, 2009; Visvader and Smith, 2011 + luminal progenitor-like population ( Figure 4C) . Immunohistochemical analysis showed type I tumors also expressed high levels of CD61, contained Aldh1 + cells, and expressed low levels of Gata3 ( Figures 4D and S2B) (Ginestier et al., 2007; Visvader, 2009; Visvader and Smith, 2011) . Type II tumors show fewer CD61 + cells, and were almost completely negative for Aldh1. However, Vimentin and Twist, two markers associated with EMT, were broadly expressed in type II, but not type I, tumors ( Figure 4D ). Phospho-Akt, a marker of PI3K signaling, was evident in type II tumors and at a somewhat lower level in type I tumors ( Figure 4D ). Thus, based on histology, and Notch2 ICD were present in Lfng mutant tumors as compared to control non-tumor-bearing glands from the same animal (Figure 5B) . Specific antibodies to detect murine Notch3 ICD and Notch4 ICD are currently unavailable; however, expression and processing of both proteins were changed in Lfng mutant tumors ( Figure S3 ). For Notch4, increased accumulation of a C-terminal fragment consistent with Notch4 ICD was observed ( Figure S3 ).
Finally, Jagged1 protein was expressed in Lfng mutant tumors, as were the protein products of Notch target genes, Cyclin D1 and c-Myc ( Figure 5C ). Thus, Lfng gene deletion results in Notch activation in these tumors, and is consistent with induction of Jagged/Notch target genes, CyclinD1 and c-Myc.
Met/Caveolin Gene Amplification and Signaling in Lfng Mutant Tumors
Next, to identify cooperative events in Lfng mutant tumors, we performed aCGH (array comparative genomic hybridization) on DNA isolated from 5 Lfng conditional mutant tumors as compared to non-tumor DNA isolated from control tissue. While copy number gains and losses were noted in many regions across the genome, the only common abnormality involved amplification of a small locus at chromosome 6A2 ( Figures S4A  and S4B ). This was observed in 4 out of 5 tumor samples, the exception being a Lfng flox/+ ;MMTV-Cre mammary tumor. The overlapping region with copy number gains in each of the four tumors contained 13 genes including the tyrosine kinase Met, and neighboring Cav1 and 2 genes ( Figure 6A ). This locus is amplified and/or overexpressed in BLBC in humans and in mammary tumors from Brca1 d11/co ; p53
; MMTV-Cre mice (Savage et al., 2007; Smolen et al., 2006) . To determine which, if any, of these genes were overexpressed in Lfng mutant tumors, we screened our transcriptional profiling data for expression of genes within this region. Indeed, expression of several, including Met, Cav1 and 2, was significantly elevated in Lfng mutant tumors ( Figure 6B ). Interestingly, high-level MET expression has been noted in aggressive human breast cancer, particularly in breast tumors with EMT features (Gastaldi et al., 2010; Ponzo and Park, 2010) , and expression of oncogenic Met can induce basal-like mammary tumors in transgenic mice (Graveel et al., 2009; Ponzo et al., 2009 ). We next used western analysis to test for elevated Met accumulation and activation in Lfng mutant tumors. As shown in Figure 6C , Lfng mutant tumors showed dramatically increased Met expression and activation. Overexpressed Met could still depend on HGF ligand for activation. Indeed, Hgfa was identified as overrepresented in gene expression signatures from Lfng mutant tumors in comparison to other mouse models of breast cancer analyzed (Table S1) , and HGFa expression was detected by western analysis of Lfng mutant tumors (data not shown). Next, we analyzed Caveolin 1/2 expression in Lfng tumors. In the normal mammary gland, Caveolin 1 is very highly expressed in endothelial cells, adipocytes, and basally localized myoepithelium. High-level expression was also seen in type I and II tumor cells ( Figure 6D ). We analyzed Caveolin 2 expression by western blot, and in each case, it was elevated in tumor cells in comparison to nontumorous mammary tissue from the same animal ( Figure 6E ). Caveolin expression has been linked to enhanced Insulin and Igf-1R signaling (Lu et al., 2008; Ravid et al., 2005; Salani et al., 2008) , and elevated Igf-1R signaling can induce mammary tumors in mice . We therefore analyzed InsR and Igf-1R signaling at the level of Irs1/2 tyrosine phosphorylation. Indeed, Irs tyrosine phosphorylation was elevated in Lfng mutant mammary tumors ( Figure 6E ). Thus, Lfng mutant tumors have selected for activation of receptors that are more highly expressed or active in basal cells (Hvid et al., 2011; Niranjan et al., 1995) .
Low-Level LFNG Expression Is a Hallmark of Basal-like Breast Cancer in Humans
Because deletion of Lfng caused basal-like and claudin-low mammary tumors in mice, we analyzed LFNG expression in human breast cancer. First, we screened publically available gene expression data from 676 human breast cancers with linked clinical-pathological information. Interestingly, reduced LFNG expression was associated with high tumor grade, with ERa/PR/HER2 triple-negative status, and most significantly, with the basal-like molecular subtype ( Figures S5A and S5B) . To the contrary, elevated LFNG expression was noted in ER See also Figure S3 .
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Lfng Suppresses Basal-like Breast Tumor Formation tumors and HER2 + tumors ( Figures S5A and S5B ). Nevins and colleagues have recently identified gene expression signatures for activation of signaling pathways in breast cancer (Gatza et al., 2010) . We therefore tested for activation of these pathways in relation to LFNG gene expression. Several oncogenic pathways including those associated with a high rate of proliferation (Myc and E2F1), as well as stem cell signaling (b-catenin), show increased activity in tumors with low LFNG expression, whereas the p53 pathway activity is significantly depressed in LFNG low tumors ( Figure S5B ). As Met was amplified and overexpressed in our Lfng mutant mammary tumors, we also tested for MET expression. As previously noted, basal-like and triple negative breast tumors expressed elevated levels of MET ( Figure S5B and S5C) (Graveel et al., 2009; Ponzo et al., 2009) . Perhaps not surprisingly, low LFNG expression was correlated with elevated MET levels ( Figure S5C ).
Finally, a number of studies have highlighted a potential role for Notch receptor signaling in human breast cancer. Therefore, we performed cluster analysis on the UNC publicly available microarray data set (UNC337, GSE18229), and evaluated expression of NOTCH pathway genes in each subtype (Prat et al., 2010) . Once again, low-level LFNG expression was noted in basal-like tumors from this cohort, and also in a group of claudin-low tumors ( Figures 7A and 7B) . HES1, and to a lesser extent HEY1, showed reduced expression in a subset of basal tumors ( Figure 7A ). In contrast, c-Myc and NOTCH1 expression were elevated in BLBC (Figures 7A and 7B) . Thus, LFNG expression is consistently low in human basal-like and a subset of claudinlow breast cancers. These data help explain how Jagged-mediated Notch activation stimulates proliferation as well as invasion (Shimizu et al., 2011) of BLBC and other triplenegative breast tumors.
DISCUSSION
With the discovery of Notch4 as a target in MMTV-induced mammary tumor formation, it became clear that elevated Notch signaling was oncogenic in mammary epithelium (Callahan and Smith, 2000) . Indeed, translocations that activate NOTCH1 or 2 have been identified in some triple-negative breast cancers and cell lines . In this study we have identified a role for Lfng deletion (mouse) or downregulation (human) in BLBC, associated with activation of Notch ICD accumulation and induction of oncogenic Notch target gene expression. Multiple Notch receptors are expressed in the mammary gland and several of these are believed to function in breast cancer (Harrison et al., 2010; Haughian et al., 2012; Osipo et al., 2008; Sansone et al., 2007; Yamaguchi et al., 2008) . Based on accumulation of luminal progenitor-like cells in Lfng mutant basallike tumors, our data reinforce the finding that elevated Notch signaling enhances proliferation of this compartment (Bouras et al., 2008 ). Interestingly, a low level of LFNG is observed in the vast majority of BLBCs (Figure 7 ). It will be important to see how these tumors compare in phenotype to the small fraction of triple-negative tumors with Notch-activating translocations .
Deletion of Lfng in our conditional mutant mice results in reduced expression of the Notch reporter gene during puberty. Based on the known function of Fringe proteins to enhance Delta ligand-mediated signaling, these data suggest that Dll1, expressed in myoepithelial cells, functions to activate Notch in Lfng-expressing MaSCs or bipotent progenitors. In adults, Jagged1 expression is enhanced within the epithelial compartment (Figure 1) (Reedijk et al., 2005) . Loss of Lfng in this setting would be expected to increase Jagged/Notch signaling and to induce luminal cell fate commitment as well as proliferation of luminal progenitors (Bouras et al., 2008) . It is this effect, in older animals, that is likely responsible for establishing both lineage bias and progenitor compartment expansion to set the stage for transformation.
Human BLBCs contain dozens of mutations that presumably cooperate to transform mammary progenitor cells (Ding et al., 2010) . Recent data indicate that cooperative interactions occur between mutations in a number of tumor suppressors, including RB1, TP53, BRCA1, PTEN, and PTPN12 (Carey et al., 2010; Foulkes et al., 2010; Herschkowitz et al., 2008; Holstege et al., 2010; Jiang et al., 2010 Jiang et al., , 2011 Kobayashi, 2008; Rakha et al., 2008; Saal et al., 2008; Sun et al., 2011) . Despite this, it has not been clear how oncogenic pathways interact to control lineage in basal tumors. As a first step to define cooperative pathways in Lfng mutant tumors, we performed aCGH analysis and found Met/Cav gene amplification and enhanced signaling to represent a common event in this context. Indeed, low-level LFNG expression and elevated MET signaling are both associated with BLBC in humans (Gastaldi et al., 2010; Ponzo and Park, 2010) . Interestingly, this same amplicon is selected for in brain tumors that occur in Pten/p53 conditional mutant mice, but not in brain tumors from mice with conditional deletion of Pten, p53, and Rb (Chow et al., 2011) , suggesting that Met/ Cav gene amplification/overexpression may perform similar oncogenic functions as Rb gene deletion, an event also associated with BLBC in humans and mice (Herschkowitz et al., 2008; Jiang et al., 2010) . The consistent selection for amplification of the Met/Cav locus in Lfng mutant tumors is striking, and speaks to an emerging concept in cancer whereby genes that function synergistically to enhance signaling through a specific oncogenic signaling pathway will frequently be co-selected during tumor formation or progression. For example, the chromosome 17q amplicon in HER2 + breast tumors encodes the HER2 receptor and also the Grb7 adaptor protein, which binds to HER2 protein to facilitate signal transduction (Andrechek et al., 2003; Stein et al., 1994) . In addition, the 9p24 amplicon associated with mediastinal B cell lymphoma contains several genes that interact synergistically to enhance IL-13 signaling (Rui et al., 2010) . The consistent selection for amplification of the Met/Cav gene locus in Lfng mutant tumors, and common overexpression of this locus in human BLBC, also leads to synergistic interactions. As depicted in Figure 8 , Lfng gene loss or reduced expression of LFNG in human tumors cooperates with Met and Cav1/2 gene amplification at multiple levels. First, elevated Notch signaling as a result of decreased Lfng function, promotes specification and proliferation of luminal progenitors (Bouras et al., 2008) . In addition, Met amplification would naturally result in elevated Met signaling. This effect should be enhanced through absence of Hes/Hey-mediated silencing of the Met gene promoter (Stella et al., 2005) . Finally, Caveolin1/2 overexpression would be expected to enhance signaling through the insulin receptor and/or Igf-1R ( See also Figure S4 .
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Lfng Suppresses Basal-like Breast Tumor Formation Monaghan-Benson et al., 2008; Shimizu et al., 2011) and activation of HGF (Naldini et al., 1995) . The specific combination of oncogenic mutations would therefore have the effect of promoting a luminal progenitor fate with lower integrin expression, and therefore reduced survival signaling from the basement membrane. The selection for elevated Met and InsR/Igf-1R signaling can thus provide a basal survival-type signal for these luminal progenitor tumor cells. Thus, combination therapy targeting Notch, Met and InsR/Igf-1R or other elements in this hybrid luminal/basal signaling network may prove effective for treatment of BLBC with low LFNG gene expression plus overexpression of the MET/CAV locus on chromosome 7q31.
EXPERIMENTAL PROCEDURES Mice
Mice were housed under standard condition and protocols approved by animal care committees at the Hospital for Sick Children and Toronto Center for Phenogenomics. The specific mice used for this study are described elsewhere (Duncan et al., 2005; Hrabĕ de Angelis et al., 1997; Xu et al., 2010; Zhang and Gridley, 1998 mental Experimental Procedures. Fluorescence was recorded using BD LSR-II flow cytometer and analyzed with FlowJo 9.1 (Treestar). Dead cells were excluded based on propidium iodide staining. Distinct populations of tumor cells were serially diluted, suspended in matrigel, and then injected into the mammary fat pad of 4-week-old FVB mice .
Array Comparative Genomic Hybridization
Genomic DNAs were purified using DNAeasy kits (QIAGEN) combined with phenol-chloroform extraction. Array CGH was conducted at the Center for Applied Genomics, Hospital for Sick Children. Briefly, 2.0 mg genomic DNA was labeled using a BioPrime kit (Invitrogen), hybridized to Agilent mouse 1 3 1M CGH arrays, and scanned. Genomic DNA from non-tumor mammary tissue of the same animal was used as reference for tumor samples.
Microarray Gene Expression Analysis
Mouse mammary tumor RNA was purified using an RNeasy mini Kit (QIAGEN). Microarray hybridizations were performed as described in Herschkowitz et al. except that samples were hybridized to custom 180K Agilent microarrays (BARCODE25503) and were scanned using an Agilent Microarray Scanner with Feature Extraction software (Herschkowitz et al., 2007) . Analysis of the North Carolina breast cancer data set has been described (Prat et al., 2010) . See Supplemental Experimental Procedures for gene expression analysis of mouse mammary tumors and analysis of LFNG expression in 676 human breast cancers.
Statistics
All data are presented as mean ± standard error (SE). For two group comparisons, two-tailed Student's t test was used. For fold changes compared to 1, one-tailed one sample t test was used. A p value of 0.05 or less was considered statistically significant. Mouse tumor-free survival was analyzed by the Kaplan-Meier method and compared by a nonparametric log-rank test. Frequency of tumor-initiating cells was calculated using L-Calc software (StemCell Technologies).
ACCESSION NUMBERS
Transcriptional profiling data and aCGH data have been deposited in the GEO database (http://www.ncbi.nlm.nih.gov/geo/; accession numbers GSE28712 and GSE35855, respectively). 
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